Chemical Synthesis of Highly Congested gp120 V1V2 N-Glycopeptide Antigens for Potential HIV-1-Directed Vaccines.
- Resource Type
- Article
- Authors
- Aussedat, Baptiste; Vohra, Yusuf; Park, Peter K.; Fernández-Tejada, Alberto; Alam, S. Munir; Dennison, S. Moses; Jaeger, Frederick H.; Anasti, Kara; Stewart, Shelley; Blinn, Julie H.; Hua-Xin Liao; Sodroski, Joseph G.; Haynes, Barton F.; Danishefsky, Samuel J.
- Source
- Journal of the American Chemical Society. 9/4/2013, Vol. 135 Issue 35, p13113-13120. 8p.
- Subject
- *HIV infections
*THERAPEUTICS
*HIV prevention
*AIDS vaccines
*IMMUNOGENETICS
*HIV antibodies
*EPITOPES
*GLYCOPEPTIDES
*MONOCLONAL antibodies
- Language
- ISSN
- 0002-7863
Critical to the search for an effective HIV-1 vaccine is the development of immunogens capable of inducing broadly neutralizing antibodies (BnAbs). A key first step in this process is to design immunogens that can be recognized by known BnAbs. The monoclonal antibody PG9 is a BnAb that neutralizes diverse strains of HIV-1 by targeting a conserved carbohydrate-protein epitope in the variable 1 and 2 (V1V2) region of the viral envelope. Important for recognition are two closely spaced N-glycans at Asn160 and Asn156. Glycopeptides containing this synthetically challenging bis-N-glycosylated motif were prepared by convergent assembly, and were shown to be antigenic for PG9. Synthetic glycopeptides such as these may be useful for the development of HIV-1 vaccines based on the envelope V1V2 BnAb epitope. [ABSTRACT FROM AUTHOR]